Article
A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer.
The Prostate - 1 Jul 2021
Wang Victoria, Geybels Milan S, Jordahl Kristina M, Gerke Travis, Hamid Anis, Penney Kathryn L, Markt Sarah C, Freedman Matthew, Pomerantz Mark, Lee Gwo-Shu M, Rana Huma, Börnigen Daniela, Rebbeck Timothy R, Huttenhower Curtis, Eeles Ros A, Stanford Janet L, Consortium Practical, Berndt Sonja I, Claessens Frank, Sørensen Karina D, Park Jong Y, Vega Ana, Usmani Nawaid, Mucci Lorelei, Sweeney Christopher J
Abstract excerpt
BACKGROUND: Inflammation and one of its mediators, NF-kappa B (NFκB), have been implicated in prostate cancer carcinogenesis. We assessed whether germline polymorphisms associated with NFκB are associated with the risk of developing lethal disease (metastases or death from prostate cancer). METHODS: Using a Bayesian approach leveraging NFκB biology with integration of publicly available datasets we used a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.